CausesBy Mayo Clinic staff
Cerebral palsy is caused by an abnormality or disruption in brain development, usually before a child is born. In many cases, the exact trigger of this abnormality isn't known. Factors that may lead to problems with brain development include:
- Random mutations in genes that control brain development
- Maternal infections that affect the developing fetus
- Fetal stroke, a disruption of blood supply to the developing brain
- Lack of oxygen to the brain (asphyxia) related to difficult labor or delivery
- Infant infections that cause inflammation in or around the brain
- Traumatic head injury to an infant from a motor vehicle accident, fall or child abuse
- Cerebral palsy: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/cerebral_palsy/detail_cerebral_palsy.htm. Accessed Sept. 27, 2010.
- Evaluating and diagnosing the child with cerebral palsy. American Academy of Neurology. http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.view&guideline=124. Accessed Sept. 27, 2010.
- Cerebral palsy. American Academy of Pediatrics. http://www.healthychildren.org/English/health-issues/conditions/developmental-disabilities/Pages/Cerebral-Palsy.aspx. Accessed Sept. 28, 2010.
- Krigger KW. Cerebral palsy: An overview. American Family Physician. 2006;73:91.
- Ashwal S, et al. Practice parameter: Diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004;62:851.
- Cerebral palsy: Drug treatments for spasticity in children and adolescents. American Academy of Neurology. http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.view&guideline=389. Accessed Sept. 27, 2010.
- Delgado MR, et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:336.
- Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm. Accessed Sept. 30, 2010.
- Patterson MC (expert opinion). Mayo Clinic, Rochester, Minn. Nov. 9, 2010.